Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has been issued a Registration Certificate from the Registration Committee for Pharmaceutical Companies & their Products of the Qatar Ministry of Public Health granting marketing authorization for the commercial distribution and sale of Endari® in the country. The company also announced that it received its first major purchase order from its distributor in the Kingdom of Saudi Arabia, wh
By Brad Sorensen, CFA OTC:EMMA READ THE FULL EMMA RESEARCH REPORT EMMA (OTC:EMMA) is a commercial stage biopharma company bringing relief to sickle cell sufferers and looking to expand their reach. Emmaus Life Sciences, Inc. is expanding the reach of Endari, its treatment for sickle cell disease, while also pursuing other treatments to add to its portfolio. The company reported 3Q 2022 earnings
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022 and provided a business update.